Group 1 - GLP-1 receptor agonists are being recognized for their potential independent cardiac protective effects, beyond their established roles in diabetes and weight loss, with a recent study indicating a risk reduction for heart failure by approximately 50% through GLP-1 receptor activation [1][2] - The findings challenge the traditional view that GLP-1 drugs are only suitable for diabetic or obese patients, providing a new theoretical basis for their use in treating heart failure and supporting broader applications in heart failure patient populations [2] - Major players in the GLP-1 drug market include Eli Lilly's tirzepatide and Novo Nordisk's semaglutide, while new entrants from China, such as Innovent Biologics' mazdutide and Xian Janssen's enogratide, are emerging [2] Group 2 - Pfizer is actively developing next-generation GLP-1 drugs, with recent mid-stage trial data showing over a 12% weight reduction in non-diabetic patients, stemming from its acquisition of biotechnology company Metsera for over $10 billion [3]